Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| aTYR PHARMA INCLIFE · Entity 7233 | VP, Product Protection | September 13, 2016 | September 15, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
aTYR PHARMA INC
Report date September 13, 2016 · Filed September 15, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2026-09-13 | Direct | 25,000 |
Reported balance
After 2016-09-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-13 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2016 Filed Sep 15, 2016 23:26 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-16-141679 · doc4.xml · derivative · entry 1 Cubitt Andrew · CIK 0001641212 · VP, Product Protection 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.